Biogen eyes potential acquisitions - Stat News
Reuters
Published Jan 13, 2022 03:34PM ET
(Reuters) - Biogen Inc (NASDAQ:BIIB) is working with investment bank Goldman Sachs (NYSE:GS) to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.
The report said the company's board had warmed to the idea of acquisitions amid the turmoil surrounding its controversial Alzheimer's drug Aduhelm.
Biogen did not immediately reply to a Reuters request for comment on the report.
On Tuesday, the U.S. Centers for Medicaid and Medicare Services (CMS) said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials, threatening sales of the drug.
In a conference call with analysts on Thursday, Biogen Chief Executive Officer Michel Vounatsos said the management was engaging with the board on "tactical, short-term measures, but also strategic options".
Vounatsos was replying to a query on whether the company would consider any strategic options to protect shareholder value, especially in light of the Aduhelm controversy.
Aduhelm was approved by the U.S. Food and Drug Administration in June despite a vote by the agency's outside advisers that the treatment's clinical benefits had not been proven.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.